The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

The British government is set to explore whether Eli Lilly’s weight-loss drug could play a pivotal role in getting people ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

All the evidence gathered from the five-year trial will be used to demonstrate the long-term effect of weight loss medication ...